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Ninety-four AMI patients were studied for their serum zinc, 
copper, selenium and magnesium concentration. 24% of 
patients were hypomagnesemic on admission during AML 
Zinc concentration was lowered during AMI and severe 
hypozincemia (less than 8 ^mol/L) were found in 25% of the 
patients. Low zinc level, high copper/zinc ratio, in addition to 
impaired renal function and advanced age were independent 
risk factors for mortality after AMI. There was no evidence for 
a lower selenium level among AMI patients. The results 
indicated that hypomagnesemia was not a rare event in AMI 
patients. Although it did not affect mortality, appropriate 
supplement with magnesium is indicated. Hypotheses were 
proposed for the effect of low zinc concentration on patient 
mortality including acute phase reaction, nutritional depletion 
and size of infarct. 
Iin another group of patients on digoxin treatment, a high 
prevalence of hypomagnesemia and hypozincemia were also 
found. Monitoring of these elements for patients with chronic 
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found. Monitoring of these elements for patients with chronic 
illness and receiving long term medication is indicated. 
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1 LITERATURE REVIEW 
1.1 MAGNESIUM 
1.1.1 GENERAL FUNCTION OF MAGNESIUM 
I. MAGNESIUM IS NOT A TRUE TRACE ELEMENT 
It is the fourth most abundant cation in the body and the 
second most abundant intracellular cation after potassium. As an 
alkaline earth metal, magnesium has chemical properties distinct 
from those of the transition metals. Compared with the transition 
metals, magnesium interacts with other chemical species with a 
strong electrostatic bonding component and a relative preference 
for oxygen over nitrogen atoms. There are two major roles for 
magnesium in biological systems: it can compete with calcium for 
binding sites on proteins and membranes, and form chelates with 
important intracellular anionic ligands, notably adenosine 
triphosphate (ATP)[H.Sigel et al, 1990] 
3 
II. AN ESSENTLVL COFACTOR FOR ENZYMES 
Magnesium ion (Mg^+) is pivotal in the transfer, storage 
and utilization of energy. It regulates and catalyzes some 300 
enzyme systems. Magnesium acts as an essential cofactor for 
enzymes concerned with [Carfmkel.L, 1985]: 
1) The Krebs cycle (i.e. pyruvate dehydrogenase, isocitrate 
dehydrogenase, oxoglutarate dehydrogenase, and succinyl-CoA 
synthetase). 
2) glycolysis (i.e. hexokinase, phosphoglucose isomerase, 
phosphofmctokinase, phosphoglycerate kinase, 
phosphoglyceromutase, enolase, and pyruvate kinase) 
3) oxidative metabolism 
4) transmembrane transport of other cations such as calcium, 
potassium and sodium. 
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Magnesium can affect enzyme activity by: 
(1) binding the active site of the enzyme (pyruvate kinase, 
enolase) 
(2) by ligand binding (ATP-requiring enzymes) 
(3) by causing conformational changes during the catalytic 
process (Na-K-ATPase) 
(4) by promoting aggregation of multienzyme complexes(e.g., 
aldehyde dehydrogenase) 
Magnesium's role in regulating cell membrane permeability 
and transmembrane electrolyte flux are widely accepted. Reduced 
extracellular magnesium concentrations result in an increase in 
transmission across the myoneural junction. Magnesium also acts 
to maintain a low resting concentration of intracellular calcium 
ions; it modulates and controls cell Ca:+ entry and Ca"^ release 
from the sarcoplasmic and endoplasmic reticulum, a necessary 
prerequisite for the trigger function of calcium in several cellular 
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processes [W.E.C.Wacker, 1980]. 
Within the cell nucleus, Mg^+ regulates DNA synthesis. Large 
numbers of Mg^+ ions are bound to the pentose-phosphate 
backbone of DNA. By regulating DNA and RNA(i.e., RNA 
synthetase, mRNA attachment to ribosomes, etc) synthesis and 
structure, Mg^+ plays a vital role in regulating cell growth, 
reproduction and membrane structure.[Cameron IL et al, 1989] 
Magnesium influences the secretion of PTH by the parathyroid 
glands, and severe hypomagnesemia may cause 
hypoparathyrioidism. 
1.1.2 ABSORPTION AND METABOLISM OF MAGNESIUM 
!. Distribution in the human body 
The adult human body (70 kg) contains 21 to 28 g of 
magnesium (approximately 1 mol). About 70% total body 
magnesium is present in the skeleton, 20% in skeletal muscle, 8% 
in other cells, and about 2% in extracellular fluid [J.A.F.Rook et 
al, 1962] 
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The main dietary sources of magnesium are vegetables 
containing chlorophyll, seafood, nuts, and grains contain 
appreciable amounts, whereas oils, fats. And sugars contain very 
little. In addition, drinking water, especially hard water, may be a 
major source of magnesium. The Recommended Dietary 
Allowance (RDA) for magnesium is listed in Table 1-1. 
About 30% of dietary magnesium is absorbed from the small 
intestin. However, this may vary widely because intestinal 
absorption is inversely related to magnesium intake. Magnesium 
absorption is affected by malabsorption syndromes, factors that 
affect transit time, calcium, phosphate, protein, lactose, or 
ingested alcohol. Vitamin D has not been shown to affect 
magnesium absorption [J. Behar, 1974:. 
The major excretory pathway for absorbed magnesium is via 
the kidney. Magnesium homeostasis is achieved primarily via 
renal regulation. During periods of magnesium depletion, kidney 
magnesium excretion can be markedly reduced. The thick 
ascending loop of Henle is the major segment involved in control 
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of renal magnesium balance via both active and passive transport 
mechanisms. The amount of magnesium being reabsorbed in the 
distal tubule is load-dependent and has been shown to be closely 
related to sodium, calcium, phosphate,and potassium reabsorption 
and to the levels of various hormones (parathyroid hormone, 
calcitonin, ADH). The major part of magnesium in plasma (about 
55-60%) is present in the free ion form , and about 6-13 % is 
complexed to phosphate and citrate; the remainder is bound to 
protein, the majority being bound to albumin[Tietz et al, 1994].* 
1.1.3 CLINICAL ASPECTS 
I. Symptoms of hypomagnesimia 
The symptoms of hypomagnesemia are very similar to those 
of hypocalcaemia: impairment of neuromuscular function; 
examples are hyperirritability, tetany, tremor, convulsions, muscle 
weakness and electrocardiographic changes [M.J.Halpem，1985". 
Magnesium deprivation has been associated with 
cardiovascular disease through epidemiological evidence that 
relates low magnesium intake to a high incidence of cardiac 
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deaths, particularly in soft-water areas where magnesium intakes 
are higher. Hypertension, myocardial infarction, cardiac 
dysrhythmias, coronary vasospasm, and premature atherosclerosis 
also have been linked to magnesium depletion [R.Whang et al, 
1982]. 
II. Causes of hypomagnesemia 
(1) Dietary insufficiency accompanied by intestinal 
malabsorption, severe vomiting, diarrhoea or other causes of 
intestinal loss. (2) Osmotic diuresis such as occurs in diabetes 
mellitus. Prolonged use ofdiuretic treatment especially when 
dietary intake has been marginal. (3) Cytotoxic drug therapy 
such as cisplatinum which impairs renal tubular reabsorption of 
magnesium. (4) Treatment with immunosuppressant drugs. 
[MJ.Halpem, 1985] 
Human magnesium deficiency, as indicated by reduced serum 
magnesium concetration (hypomagnesemia), occurs with either 
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normal or reduced serum calcium concentrations. 
Hypomagnesemia may be a secondary effect in hypocalcemic or 
calcium-deficient tetany. Yet a hypomagnesemic-normocalcemic 
tetany has been described that can be effectively treated with 
magnesium supplementation alone. During tetany, serum 
magnesium concentration of0.15 to 0.5 mmol/L accompanied by 
normal serum calcium and pH have been reported. There is 
evidence that tetany accompanied by hypocalcemia and 
hypomagnesemia may not be optimally treated with calcium 
administration alone. Decreased serum potassium concentrations 
(hypokalemia) have also been found to accompany magnesium 
depletion. The occurrence of otherwise unexplained hypokalemia 
or hypocalcemia should suggest magnesium deficiency [Tietz et 
al, 1994]. 
Hypomagnesemia have been associated with chronic 
alcoholism, childhood malnutrition, lactation, malabsorption, 
acute pancreatitis, hypothyroidism, chronic glomerulonephritis, 
aldosteronism, digitalis intoxication, and prolonged intravenous 
feeding. Magnesium depletion occurs in condition that disrupt the 
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normal renal conservation of magnesium, for example, in patients 
with renal tubular reabsorption defects and those taking 
chlorothiazides, ammonium chloride, or mercurial diuretics for 
congestive heart failure [Wong ET et al, 1982；. 
Increased serum magnesium concentrations have been 
observed in dehydration, severe diabetic acidosis, and Addison's 
disease [Ryzen E et al, 1985]. Conditions that interfere with 
glomerular filtration, for example, uremia, result in retention of 
magnesium and hence elevation of serum concentrations. 
Hypermagnesemia leads to an increase in the atrioventricular 
conduction time of the electrocardiogram.[Cohen L et al, 1984" 
1.1.4 METHODS OF DETERMINATION OF MAGNESIUM 
I. Atomic Absorption Spectrophotometry (AAS) 
Atomic absorption spectrophotometry is the preferred 
technique for the determination of magnesium in biological 
‘ specimens. This is due to its high sensitivity and specificity, small 
sample size requirements. No interferences have been observed to 
Mg detection from large concentrations of sodium, potassium, 
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calcium, and phosphorus, which are often present in biological 
smaples [W.Slavin, 1967:. 
Graphite furnace atomic absorption spectrometry is an 
excellent method to provide sub-ng/ml minimum detection limits. 
II Colormetric Methods 
Many fluorometric (8-hydroxyquinoline) and colormetric 
methods have been used for determining serum magnesium. The 
colored calmagite-Mg complex is formed immediately upon 
mixing calmagite reagent with serum and is stable for over 30 
min. Serum magnesium is calculated by comparing the spectral 
absorbance of the sample at 520 nm with magnesium iodate 
calibrators. The method is simple and rapid.[Tietz et al, 1994] 
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1.2 zmc 
1.2.1 GENERAL FUNCTION OF ZINC 
Zinc is an essential trace element. Research has elucidated 
many of its specific metabolic interactions since zinc deficiency 
was first described in humans in the early 1960s. Zinc is an 
essential component of over 200 metalloenzymes with a wide 
range of functions eg. carbonic anhydrase, alkaline phosphate, 
RNA，and DNA polymerases, thymidine kinase, 
carboxypeptidases, and alcohol dehydrogenase [J.G.Reinhold et 
al, 1976]. 
The zinc atoms are an integral, firmly bound part o f the 
metalloprotein molecule and are often involved in the active site; 
they also contribute to the conformation and structural stability of 
many metalloenzymes,[Tietz et al, 1994' 
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Zinc plays a role in various physiological functions including 
growth, wound healing, skin integrity, functioning of male 
reproductive organs and fertility, integrity of the immune system, 
anti-inflammatory actions, protection against free radicals, and 
functioning of taste and eyesight [R.L.Willson，1989；. 
1.2.2 ABSORPTION AND METABOLISM OF ZINC 
I. Distribution in the human body 
Zinc is second to iron as the most abundant trace element in 
the body. The body content in a 70-kg man is about 2.5 g. Zinc 
are located mainly in muscle (60%), bone(30%), prostrate, semen, 
liver, kidney and retina [MJJacksin, 1989]. The zinc content of 
erythrocytes is about 10 times that of plasma because of their rich 
content of carbonic anhydrase and other zinc-containing enzymes 
[Tietz et al, 1994]. 
II. Intake of Zinc 
Zinc is present in all protein-rich foods such as meat, fish, and 
dairy products. The absorption of zinc is reduced in the presence 
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of phytates (inositol phosphates), cellulose, hemicellulose, and 
other dietary fibers from vegetables and cereal grains. Westem 
diets generally supply adults with 10 to 15 mg ZnAi. The RDA for 
zinc are listed in Table 1-1. 
III. Absorption 
Around 30% of ingested zinc is absorbed. Zinc absorption 
occurs mostly in the small intestine and especially in jejunum. 
Zn2+ is absorbed possibly in the form of complexes with amino 
acids, citrate, etc. It is an active, energy dependent process. Zinc 
absorption is variable and is dependent upon a variety of factors. 
Cereals, for example, are rich in zinc, but the absorption is poor 
due to the phytate ligands. Proteins and amino acids present in 
foods increase the absorption of zinc. The technologies used in 
food processing may lead to an increase or a decrease of zinc 
content in the foods psLW.Solomons, 1982；. 
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IV. Transportation 
In the blood, zinc is distributed between red blood cells 
(80%), plasma (17%), and white blood cells (3%). In plasma, 90% 
of zinc is bound to albumin and 10% to a2-macr0gl0bulin with a 
small amount associated with transferrin, glycoprotein, 
transthyretine and free amino acids [W.R.Harris, 1983；. 
V. Excretion 
Zinc is mainly excreted via the feces. Pancreatic secretion 
accounts for about 25% of total excretion. Biliary losses are small. 
Loss through urine, sweat, milk, and sperm are minor. 
1.2.3 CLINICAL ASPECT 
I. General Causes ofzinc deficiency: 
Nutritional zinc deficiency in humans is fairly prevalent 
throughout the world. It occurs in both adults and children 
through lack of dietary zinc. Old age, pregnancy, lactation, and 
alcoholism are also associated with a higher incidence of poor 
zinc nutrition. 
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II. Diseases Causing Zinc Deficiency: 
1) hepatic cirrhosis 
2) renal disease 
3) bumed patients 
4) neoplastic and inflammatory diseases 
5) genetic disorder of zinc metabolism-acrodermatitis 
enteropathica: This is a rare inherited disease which manifests 
itself in infancy as retarded growth, hypogonadism, 
dermatological and ophthalmic lesions, and gastrointestinal 
disturbances. The patients exhibit lowered plasma zinc 
concentrations. Untreated, the prognosis is poor, but oral zinc 
therapy (zinc sulfate) leads to complete remission. 
6) Zinc is antagonized by cadmium, and zinc deficiency can be a 
consequence of chronic cadmium poisoning. 
1 7 
III. Iatrogenic Causes of Zinc Deficiency: 
Zinc and other trace element deficiency is known to occur in 
patients on synthetic diets therapies or total intravenous nutrition 
(TPN) for a long term and causes a characteristic skin rash and 
hair loss. 
Administration of anabolic and metal-chelating drugs such as 
corticosteroids and penicillamine [Tietz et al, 1994；. 
IV. clinical features 
In children, the rate of growth during rehabilitation from 
famine has been clearly related to the dietary supply of 
bioavailable zinc. 
The clinical features ofzinc deficiency exist as a spectrum; on 
one end, the symptoms may be mild or marginal, whereas on the 
other end, the symptoms are severe. The main clinical 
manifestations include skin injury, alopecia, poor wound healing, 
anorexia, loss of senses, impaired development and function of 
male reproductive organs, and immunodeficiencies. 
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1.2.4 ASSESSMENT OF THE BODY ZINC STATUS 
Laboratory tests for assessing zinc nutrition can be classified 
into two groups: those involving the analysis of zinc in a body 
tissue or fluid and those testing a zinc-dependent function. Useful 
tests in the first group include determination of the zinc content of 
plasma or serum, blood cells, urine, and saliva. Functional tests 
include measurement of activities of zinc-containing enzymes and 
assessment of taste acuity. All of the above indices have been 
shown to decrease with zinc deficiency. Other tests that are either 
too complex for routine diagnostics or not well investigated 
include skin and fingemail zinc determinations, Zn uptake by 
erythrocytes, measurement of changes of plasma zinc content 
during exercise, blood ethanol clearance, Zn retention and 
tumover, and zinc balance. 
Although the tests mentioned above have been shown to be 
related to zinc depletion in animals and humans, no single test has 
been proven to be a definitive indicator of zinc status. Test results 
must be interpreted with caution because they may be confounded 
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by clinical conditions unrelated to the subjects zinc status per se. 
Methological problems unique to trace element analysis have also 
hampered the routine diagnosis of zinc deficiency [Tietz et al, 
1994]. 
1.2.5 METHODS OF DETERMINATION OF ZINC 
The analytical methods for zinc measurements in body fluids 
include colorimetric and fluorimetric methods, AAS, neutron 
activation analysis(NAA), and inductively coupled plasma mass 
spectrometry (ICPMS). 
I. Atomic absorption spectromitry (AAS) 
Flame AAS is the analytically reliable and generally used test 
for the determination of zinc in blood, serum, plasma, tears, and 
tissues. Electothermal AAS is useful when lower levels of zinc 
are to be determined. 
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1.3 COPPER 
1.3.1 GENERAL FUNCTION OF COPPER 
Copper is a component of a wide range of intracellular 
metalloenzymes, including ceruloplasmin, cytochrome oxidase, 
superoxide dismutase, dopamine-B-hydroxylase, ascorbate 
oxidase, lysyl oxidase, and tyrosinase. 
Iron needs copper to be absorbed .Copper deficiency leads to 
anemia. Most of the copper in plasma is associated with the 
specific copper-binding protein, caeruloplasmin. And 
caeruloplasmin has a ferroxidase activity that oxidizes ferrous 
iron to the ferric state prior to its binding by plasma transferrin. 
[A.Mas et al, 1992] 
1.3.2 ABSORPTION AND METABOLISM OF COPPER 
1. Dietary intake 
The copper content of foods vary according to the mineral 
content soil in the area .from which the food is obtained. 
Among the best food sources are liver, whole-grain products, 
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almonds, green leafy vegetables, shellfish, crustaceans, 
kidneys, nuts, molasses, cauliflower, avocados, organ meat, 
eggs, poultry, and dried lgumes, whereas cows milk and dairy 
products have low copper contents. The copper content in food 
are also affected by the copper loss or contamination 
throughout processing. 
Many of the published values of the copper content of 
foods are based on older data and give erroneously high 
estimates. The RDAs for copper are shown in Table 1-1. 
Althoug copper is present in most foodstuffs, there is 
evidence that not all modem diets contain sufficient copper, 
especially when large amounts of refined carbohydrate are 
consumed. 
II. Absorption 
About 50% to 80% of the average daily dietary copper of 
around 25 ^imol (1.5 mg) is absorbed from the stomach and the 
small intestine. The mechanisms by which copper is absorbed 
and transported by the intestine are unclear. The exact role of 
2 2 
metallothionein in the intestinal absorption of copper is not 
well understood although zinc diminishes copper absorption by 
increased production of metallothionein in mucosal cells which 
then binds copper preferentially. Thus intestinal 
metallothionein may have some function in maintaining copper 
homeostasis. [T.U.Hoogenraad et al, 1983； 
Factors affecting copper absorption include gender (women 
absorbing a greater percentage than men), the amount infested, 
chemical form, and certain dietary constituents including other 
trace elements, sulfate, various amino acids, fiber, and phytates. 
Copper absorption may be impaired in patients with diffuse 
diseases affecting the small bowel such as sprue, 
lymphosarcoma, and scleroderma. 
IIL Transportation 
Absorbed copper is rapidly transported in portal blood 
bound to albumin or histidine to the liver where it is stored, 
mostly as metallothionine-like cuproproteins. Copper is 
exported to peripherial tissues mainly as ceruloplasmin which 
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is a multifunctional cuproprotein that accounts for over 95% of 
the total copper in plasma and, to a lesser extent, albumin, 
transcuprein, and amino acid. The movement of copper within 
the cell and its incorporation into cuproproteins is regulated by 
both glutathione and metallothionine.[Frieden, 1980: 
IV�Distribution 
The adult human body contains between 80 and 150 mg of 
copper which is present in all metabolically active tissues. The 
highest concentrations are found in liver (30-50 g/g dry tissue) 
and in kidney, with significant amounts in heart, brain. Muscle 
and bone copper concentrations are low but constitute about 
50% of the total-body copper because of their large mass. 
[D.H.Hamer, 1986] 
V. Homeostasis 
Copper is excreted primarily into the gut, from unabsorbed 
‘ dietary copper, and from biliary and gastrointestinal secretions. 
Biliary copper excretion ranges from 0.5 to 1.3 mg/d. 
Gastrointestinal sources include copper from gastric juice and 
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from desquamated mucosal cells. Copper losses in the urine 
and sweat amount to less than 3% of dietary intake. Menstrual 
losses of copper apparently are minor: 0.1 to 0.8 mg per period. 
1.3.3 CLINICAL ASPECT 
1. Human Copper Deficiency 
Copper deficiencies are relatively unknown. Low blood 
levels have been observed in children with copper or iron-
deficiency anemia, prematurity, malnutrition, malabsorption, 
chronic diarrhea, hyperalimentation, edema and prolonged 
feeding with total milk diets. Symptoms of a deficiency include 
general weakness, impaired respiration, osteoporosis and 
various bone and joint abnormalities, decreased pigmentation 
of the skin and general pallor and skin sores, and possible 
neurological abnormalities (hypotonia, apnea, psychomotor 
retardation). Inadequate intake can lead to neutropenia and 
hypochromic anemia. [E Frieden et al, 1983" 
Human copper deficiency has also been associated with 
zinc therapy for sickle cell disease and treatment with copper-
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chelating agents like penicillamine.[Tietz et al, 1994] 
II. Menkes Syndrome 
This is an X-linked genetic disorder characterized by focal 
cerebral and cerebeller degeneration, retardation of growth, and 
kinky or steely hair. It is an extreme form of copper deficiency 
with defect in copper transport and storage. 
III. Wilsons Disease 
A rare autosomal recessive inherited disease with abnormal 
copper metabolism, which brings about excess copper retention 
in the liver, brain, kidney, and comeas of the eye. It is 
characterized by cirrhosis of the liver, irreversible dseases in 
the central nervous system, and comeal degradation. 
IV. Copper Toxicity 
Copper is nontoxic to humans in small amounts; up to 35 
mg daily for an adult is safe. Conditions that show high copper 
blood levels include oral contraceptives, stuttering, autism, 
childhood hyperactivity, toxemia of pregnancy, premenstrual 
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tension, depression, insomnia, senility, premature baldness, 
tinnitus, facial pigmentation, painful joints, functional 
hypoglycemia, cirrhosis of the liver, hypoproteinemia, niacin 
deficiency, infections, heart attack, leukemia, and mental 
illness. It can occur subsequent to ingestion of copper-
contaminated solutions, the use of copper-containing 
intrauterine devices, the use of copper salts in animals feeds, 
and exposure to copper-containing fungicides. Systemic toxic 
effects include hemolysis, hepatic necrosis, gastrointestinal 
bleeding, oliguria, azotemia, hemoglobinuria, hematuria, 
proteinuria, tachycardia, convulsions coma, and death. [Linder 
et al, 1991] 
Because the liver is an important organ for copper storage 
and homeostatic regulation, abnormal copper metabolism is 
seen in liver disease. Elevated serum copper concentrations are 
seen in portal cirrhosis, biliary tract disease, and hepatitis, 
probably because excess copper that would normally be 
excreted in the bile is retained in the circulation. Hypocupremia 
has been observed in hemolytic jaundice, hemochromatosis, 
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and some types of hepatic cirrhosis because of the inability of 
the damaged liver to synthesize ceruloplasmin. [Tietz et al, 
1994] 
1.3.4 LABORATORY ASSESSMENT OF COPPER STATUS 
As with zinc, the assessment of copper nutrition in adult 
humans has not been perfected. There are, however, a number 
of indices that are useful in the diagnosis of human copper 
deficiency: Serum or Plasma Copper Concentrations, 
Ceruloplasmin, Superoxidase Dismutase and Cytochrome c 
Oxidase Activities, erythrocyte and leukocyte copper content, 
skin morphology, and measurements of copper retention and 
turnover. 
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Copper is associated with two main plasma proteins, 
albumin and caeruloplasmin. The major copper transport 
protein may be albumin. Concentrations of caeruloplasmin is 
unrelated to dietary copper. [Linder et al, 1981: 
1.3.5 METHODS FOR THE DETERMINATION OF COPPER 
Atomic absorption spectrophotometry after direct dilution 
is used frequently to quantitatively estimate serum copper. 
Photometric methods are also available, such as those using 
diethydithiocarbamate, bis-cyclohexanone, oxaldihydrazone 
(cuprizone), and bathocuproine as chromogens. Hemolysis is 
not a great concern for copper determinations because 
concentrations of copper in plasma and erythrocytes are nearly 
equal. Reference intervals for serum copper have been 
compiled and are higher in pregnancy, 118 to 302 g/dL (18.5-
47.4^imolA.); in children 6 to 12 years of age, 80 to 190 gAlL 
(12.6-29.9 ^imol/L); and in women, 80 to 155 g/dL (12.6-24.4 
^mol/L) than in men, 70 to 140 g/dL (11.0-22.0 ^unoLO^); and 
in infants, 20 to 70 g/dL (3.1-11.0 ^imol/L), 
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Serum ceruloplasmin can be determined by a photometric 
oxidase reaction, by immunonephelometry, or by radial 
immunodiffusion. The reference interval of 180 to 450 mg/L 
varies slightly depending upon the method used. 
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1.4 SELENIUM 
1.4.1 GENERAL FUNCTION OF SELENIUM 
Selenium is an essential element for humans. It is a cofactor 
of glutathione peroxidase. This enzyme protects membranes 
from damaging effects of peroxides (hydrogen peroxide and 
lipid hydroperoxide) by decomposing these oxidizing 
compounds. It is part of the cellular antioxidant defense system 
against free radicals. It complexes with heavy metals and 
protects against cadmium and mercury toxicity. 
It also plays a role in electron transfer functions. It also may 
affect drug-metabolizing enzymes and is involved in the 
metabolism of thyroid hormones. 
1.4.2 ABSORPTION AND METABOLISM OF SELENIUM 
I. Dietary Intake 
Selenium is present in foods as selenomethionine or 
selenocystine; selenomethionine is derived from plants and 
selenocysteine from animal sources. Good sources of se lenium 
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include seafood, organ meats, muscle meats, and whole grains. 
Fruits and vegetables are poor sources. The selenium content of 
foods varies widely from one region to another and is directly 
related to food protein content. The dietary intakes in the united 
states often tend to fall within the range of 83-129 p,g/day. 
Much lower selenium intakes are found in New Zealand (28-
32^imol/L) and Finland (30-50 ^imol/L). Most extremely low 
value come from the Keshan disease endemic area of China (7^ 
g /d). On the other hand, high dietary intakes of selenium occur 
in areas with naturally seleniferous soils such as the chronic 
selenosis area in China (4.9 mg/day). [R.A.Zingaro et ai, 1974] 
IL Absorption 
Selenium is efficiently absorbed from the gastrointestinal 
tract (varying from 35-85%) and is highest in the duodenum 
and absorption is apparently not regulated. Little is known 
about the mechanisms of absorption, it may be through a wide 
variety of mechanisms, e.g. selenomethionine is absorbed by 
the same mechanism as methionine. 
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III. Distribution 
Selenium may be transported from the gut to the liver 
mainly on VLDL and LDL [Cavalieri, 1980] and achieves its 
highest tissue concentrations in red cells, liver, spleen, heart, 
nails, and tooth enamel. It also concentrates in the testes and 
sperm, which are also more refractory to dietary deprivation. 
Mason, 1988] Selenium is present in tissues in two major 
forms: selenocysteine and selenomethionine. Selenomethionine 
can not be sysnthesized by the diet. It can replace methionine in 
a variety of proteins. Selenomethionine is considered as an 
unregulated storage compartment for selenium. When the 
dietary selenium supply is interrupted, this pool tums over and 
supplies selenium to the organism. Selenocysteine is present in 
selenoproteins eg. glutathione peroxidase, throxine-5�-
deiodinase, and selenoprotein p. Other forms of selenium may 
be present tissues but have not been fully characterized.[Tietz 
et al, 1994] 
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IV. Excretion 
Selenium is normally excreted in the urine and lungs and its 
presence in the feces is an indication of improper 
absorption.Selenium is present in bile in low concentration. 
1.4.3 CLINICAL ASPECT 
I. Keshan disease 
This is an endemic cardiomyopathy that affects primarily 
children and woman of childbearing age in certain areas of 
China, has been associated with selenium deficiency. 
II. Kashin-Beck disease 
It is an endemic osteoarthritis that occurs during adolescent 
and preadolescent years, is another disease linked to low 
selenium status in China. The exact cause of this disease is 
unknown and other factors such as mineral imbalance, 
mycotoxins in grain, or organic contaminants in drinking water 
may be involved. 
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III. Cardiomyopathy Cauesed by Selenium Deficiency 
Epidemiological studies have related cardiomyopathy with 
selenium deficiency from the consumption of low selenium 
content cereals. [X.S.Chen et al, 1980] Cardiomyopathy and 
low glutathione peroxidase activities have also been reported in 
patients on TPN who were not supplemented with selenium. 
The anticarcinogenic effects of selenium was supported by 
experiments with rodent models. 
IV. Toxicity 
Signs of chronic selenosis include hair and nails, skin 
lesions, tooth decay, malformed hooves, lameness, emaciation 
and nervous system abnormalities. Toxicity from 
administration of selenium compounds for the treatment has 
been reported (M.M.W.R., March 30, 1984). Acute selenosis 
produces severe symptoms including nausea, vomiting, hair 
• loss, nail changes, irritability, fatigue, and peripheral 
neuropathy and may die in a few hours. 
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1.4.4 ASSESSMENT 
The determinations of urinary and blood selenium are 
widely used as indicators of selenium status. Plasma or serum 
selenium concentrations are sensitive to dietary intake. Red 
cells were found with high concentration of selenium (0.23-
0.36 ^ig/ml of cells), and hemolysis can alter the serum levels. 
Most of the selenium in serum is in the form of seleocystein in 
proteins. Therefore hypoprotienemia can lead to falsely 
lowered concentration of serum selenium. In China, a 
correlation was found between hair selenium concentrations 
and blood concentrations. A functional test for assessing 
selenium nutrition is to measure glutathine peroxidase in red ‘ 
cells. [Diplock A.T., 1993] Blood and tissue selenium contents 
vary with the selenium status of the particular geographical 
area. Reported selenium concentrations in specimens from 
healthy adults are listed in tablel-3. Unfortunately, local data 
are not available. 
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1.4.5 METHODS OF DETERMEVATION OF SELENDJM 
L Methods 
Seven methods were employed for quantitating selenium in 
biological specimens: neutron activation analysis fMAA) 
Spectrofluorometry, electrothermal ASS, hydride generation 
AAS, isotope dilution mass spectrometry ^MS), XRF 
spectrometry, inductively coupled plasma (ICP). 
Recommended methods for determining selenium in biological 
specimens are flameless ASS. 
II. Analytic Problems 
一 
There is great variability in results among different 
laboratories. The main reasons for inaccurate and imprecise 
results include sampling errors, contamination, losses during 
handling, pretreatment, decomposition and steps in processing. 
The organo-selenium forms are likely to be volatile and 
therefore can be lost in step ofpyrolysis. 
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III Electrothermal (flameless) atomic absorption 
Spectrophotometry 
The conventional flame AAS is not sensitive enough for 
Selenium determination. Flameless AAS ofers high 
sensitivity, although interferences increase. Advantages of the 
flameless AAS are increased detection limits, requirement of 
low sample volumes and the simplification of sample 
pretreatment. 
1.5 INTRODUCTION TO ATOMIC ABSORPTION 
SPECTROPHOTOMETRY 
1.5.1 PRINCIPLE OF AAS 
The atom is made up of a nucleus surrounded by electrons. 
The lowest energy is known as unexcited or ground state which is 
the most stable electronic configuration of an atom. If energy of 
the right magnitude is applied to an atom, the energy will be 
absorbed by the atom and an outer electron will be promoted to a 
less stable configuration or excited state. As this state is unstable, 
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the electron will retum to its initial stable orbital position (decay 
process), and radiant energy will be emitted. The wavelength of 
light emitted is a unique property of each individual element. 
(Figure 1-1 & Figure 1-2) 
Absorbance (A) is calculated as the formula below: 
A 二 log (Io/I) 
Io is the initial intensity of the light at the resonance 
wavelenghth，I is the reduced intensity after the atomic absorption 
process in the sample cell. 
1.5.2 INSTRUMENTATION 
^ 
I. FLAME AAS 
Every absorption spectrometer must have components which 
fulfil three basic requirements: 1) a light source; 2) a sample c e l l ; . 
and 3) a means of specific light measurement. (Figure 1-3) 
The two common line sources used in atomic absorption are 
the hollow cathode lamp and electrodeless discharge lamp. The 
atomizer is a key component of the AAS instrument which 
3 9 
temperatures to bum off any sample residue which may 
remain in the fumace. 
6 Cool down - allows the flimace to retum to near 




2.1 TRACE ELEMENT DEFICIENCY IN HOSPITAL PATIENT 
Hospital patients are prone to develop malnutrition. Those 
with severe illness and at the extremes of age are particularly at 
risk. Unbalanced intake and loss from the body is the major 
reason for malnutrition. As trace elements are mostly water 
soluble, deficiency will develop early after a negative balance is 
established. It is in contrast to other predominantly lipid-soluble 
nutrients such as lipid -soluble vitamins. 
Rammohan et al (1989) evaluated the nutrient intake in 
hospitalized elderly patients o f 2 1 hospitals in the United States. 
They found that more than 60% of the patients had inadequate 
intake of a form of nutrient. Insufficient zinc and magnesium 
intake was found in 90% of patients older than 65 years. 
Therefore it is expected that deficiency of these trace 
elements are common among hospitalized patients. 
43 
2.2 MICRONUTRIENT DEFICIENCY AMONG PATIENTS 
WITH ACUTE MYOCARDIAL INFARCTION 
Heart diseases are a cause of considerable mortality in 
westem countries. It is well established that atherosclerosis is a 
multifactorial disease. Nutrition is known as one of the most 
important causes. 
2.2.1 MAGNESIUM DEFICIENCY 
The pathogenesis of low serum magnesium concentrations 
in patients with MI has not been fully elucidated. The bulk of 
experience from clinical studies mirrors the findings of animal 
experimentation, in which serum magnesium concentrations 
decreased within 1 hour following coronary occlusion and 
returned to normal by 24 to 48 hours. This decrease has been 
attributed to a number of factors, including hemodilution, renal 
• excretion, or increased intracellular influx with binding to free 
fatty acids. Careful recent work in patients with MI has 
excluded the first 2 hypotheses. The remaining hypothesis, 
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which attributes low serum magnesium concentrations in 
patients with MI to an intracellular magnesium shift mediatd by 
catecholamine-induced lipomobilization, is being supported by 
a large number of laboratory and clinical investigations. 
There were also evidence to support an effect due to the 
occurrence of lipolysis, release of long-chain free fatty acids, 
and hypomagnesemia during acute MI, during endogenous rise 
of catecholamine, during infusion of adrenaline, or other stress 
factors. The release of free fatty acids and hypomagnesemia 
occur simultaneously, and both have been attributed to 
catecholamine release. 
A large clinical trial ('Limit-2' program) studied the 
beneficial effect of IV magnesium treatment in patient suffered 
from AMI. A positive result in term of decreased acute & long 
term mortality was evident [Woods et al, 1992]. Furthermore, a 
low serum magnesium was found in high percentage ofpatients 
with AMI on admission. 
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Hypomagnesium was found to increase the risk of 
supraventricular and ventricular arrhythmia during AMI. And 
these arrhythmias are major causes of mortality and morbidity 
in AMI. Therefore magnesium level on admission could be a 
major prognostic factor in predicting outcome in these patients 
and patients found to have a low semm magnesium should be 
treated with supplement. 
However, there are a large difference in the prevalence of 
magnesium deficiency in different part of the world. A high 
percentage of hypomagnesemia was found among patients with 
chest pain by Salem et al (1996) in the United States. The 
prevalence increased further to 56% among those receiving 
diuresis. 
On the other hand, Ellis et al (1988) has not observed a 
significantly lower magnesium concentration among patients 
with AMI in a study in Australia. Therefore it is important to 
establish the prevalence of magnesium among local patients 
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with AMI in order to determine the value of IV magnesium 
therapy during the acute phase and the replacement of 
magnesium during hospital period. 
Furthermore, we also studied a group of patients who were 
on digoxin treatment. Digoxin is a potentially toxic drug and 
monitoring of its serum level does not reflect clinical toxicity in 
many occasions. Deficiency of plasma electrolytes, especially 
plasma Mg leads to an increased susceptability to digoxin 
toxicity. [Douban S, 1996] 
2.2.2 Change ofZinc and Copper in AMI 
It has been suggested that the injury induced by reperfusion 
of the ischemic myocardium could result partially from the 
cytotoxic effects of oxygen free radicals. Zinc and copper are 
involved in several of the reactions in the protection from free 
radical damage. 
I. They are components of several metalloenzymes with redox 
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capacity. This redox capacity gives them an anti-oxidizing and 
anti-reactive oxygen radical action. 
11. Zinc and Copper are also components of a protein: 
metallothione (MT). 
MT is characterized mainly by a high cysteine content 
(30%) and metal-binding capacity (7 atom Zn/mol) and 9 atom 
Cu/mol). The synthesis o f M T is induced by metals such as Cd, 
Zn and Cu, and also indirectly by non-metallic compounds as 
glucocorticoids and hormones. 
Variation in trace element can occur in several pathological 
conditions. Precisely, different alterations of Zn, Cu serum 
concentrations are produced during acute myocardial infarction 
(AMI), including a decrease of Zn and an increase in Cu serum 
levels, which take place within the first hours of AMI onset. A 
decrease in serum zinc levels has been reported after acute 
myocardial infarction with a concomitant increase in serum 
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copper. These variations have been related to the classic 
enzymatic markers of this pathology (AST, LDH, CK-MB). 
[Speich M，1988] 
In an AMI study, increased lipid peroxidation after induced 
AMI was found in rats treated with a zinc deficient diet 
[Condray et al, 1993]. There was also a large infarct size among 
those zinc deficient rats. The effect of zinc supplement on 
myocardial infarct size in dogs was studied [Lal a, 1991]. Zinc 
supplement appeared to be potentially prophylactic for limiting 
the size of myocardial infact in the dogs. 
Furthermore, a zinc study [Vilanova et al, 1997] showed 
that a low serum zinc concentration on admission was 
associated with a high mortality in AMI patients. 
Zinc is an important constituent of various metalloenzymes 
that control the synthesis of nucleic acids and proteins. 
Therefore, the fall in serum zinc levels could be due to the large 
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amount of zinc needed by the myocardial tissue to participate in 
the process of repair. However, zinc variations could also be 
explained by stress and a preexisting deficient state. Therefore 
it is important to determine if low plasma zinc is associated 
with prognosis after AMI in local patients. 
The suggestion that subclinical copper depletion contributes 
to an increased risk of coronary heart disease through instability 
of heart rhythm and hyperlipidemia is well supported 
experimentally and epidemiologically. Experimental animals 
fed copper-deficient diets and human subjects fed diets believed 
to be marginal in copper have exhibited many symptoms 
closely related to coronary heart disease. These include 
abnormal electrocardiograms, hypercholesterolemia, glucose 
intolerance, and hypertension. [Tietz et al, 1994" 
2.2.3 SELENIUM DEFICIENCY 
Substantial and growing-evidence from a variety of sources 
support the hypothesis that oxidation of low-density lipoprotein 
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may have a role in the etiology of atherosclerosis. Antioxidant 
may protect against free radical mediated carcinogenesis. The 
antioxidant properties of selenium, a constituent of glutathione 
peroxidase, are well known, and the hypothesis that this 
element may reduce cardiovascular disease has recently been 
reviewed. Although low plasma selenium has not been directly 
linked with susceptibility of low-density lipoprotein to 
oxidation, glutathione peroxidase has a major role in reducing 
peroxidation processes. Low plasma selenium has also been 
associated with increased platelet aggregability, higher 
production of thromboxane A2, and decreased production of 
prostcyclin, all of which may potentially be linked to 
cardiovascular disease. In Finland, a low-selenium region, 
persons with levels <45 [ig/L had an increased risk of 
cardiovascular death and myocardial infarction (MI). However, 
subsequent studies have yielded conflicting results. 
In a multicenter study examining the association between 
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3 MATERLVLS AND METHODS 
3.1 PATIENTS SELECTION 
3.1.1 CONTROL GROUP 
63 patients attending out-patient clinic, who had no 
history of MI and not receiving digoxin or diuretics 
treatment were recruited as control. The control group served 
to verify the already established reference intervals of serum 
zinc, copper and magnesium. It was taken for comparison of 
serum selenium with patients in AMI group. 
3.1.2 AMI GROUP 
Samples were collected from one study on evaluation of 
change in cardiac enzymes in Chinese patients. Blood was 
collected within 12 hours after presentation of chest pain. All 
serum samples were frozen at -70^C before analysis. Totally 
134 samples were analyzed. 
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Diagnosis of AMI was based on combination of 
chest pain and standard ECG criteria or enzymatic evidence 
ofmyocardial infarction. By this way, 94 patients were 
ascertained suffering from AMI. The other patients were 
classified having other unstable angina or arrhythmia. 
Mortality of the group of patients were followed up by 
hospital record and hospital computer registry. 
3.1.3 DIGOXIN TREATMENT GROUP 
101 patients requesting for a serum digoxin concentration 
monitoring were studied. An aliquot of serum was saved for 
measurement of magnesium and zinc. Serum copper was 
also measured in 21 ofthem. 
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3.2 ANALYTIC METHODS 
3.2.1 DETERMEVATION OF SERUM MAGNESIUM 
The determination of serum Magnesium was performed 
on Vitros 250 instrument (Johnson & Johnson, New 
York,USA) by a dry chemistry method. 
I. Materials 
Reagent: Vitros Mg Slides 
Reactive ingredients on the slide are 1,2-bis (o-
aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (calcium 
chelator) and 1,5 -bis (2-hydroxy-3,5 -dichlorophenyl)-3 _ 
cyanoformazan (dye). Other ingredients include pigment , • 
binders, buffer, dye solubilizer, surfactants, cross-linking 
. a g e n t . 
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II. Principle of the Assay 
The Mg Slide is a dry, multilayered, analytical element 
coated on a polyester support. A 10 i^L drop of patient 
sample is deposited on the slide and is evenly distributed by 
the spreading layer to the underlying layers. Magnesium 
(both free and protein-bound) from the sample then reacts 
with the formazan dye derivative in the reagent layer; the 
high magnesium affinity of the dye dissociates magnesium 
from binding proteins. The resulting magnesium-dye 
complex causes a shift in the dye absorption maximum from 
540 nm to 630 nm. The amount of dye complex formed is 
proportional to the magnesium concentration present in the 
sample and is measured by reflection density. 
III. Assay Protocol for Magnesium 
Test Type : Colorimetric 
Wavelength: 630 nm 
Assay Time: Approximately 5 minutes 
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Temperature: 3 7 ¾ 
Reaction Sequence 
Mg+2 + Ca+2 chelator Mg+: + Ca^^-chelator complex 
Mg+2 + formazan dye derivative pH 9.75 
1^ 
Mg -dye complex 
3.2.2 DETERMINATION OF SERUM ZINC 
CONCENTRATION 
The determination of serum zinc concentration was 
completed on the AAS 300, Perkin Elmer Spectrophotometer 




Nitric acid : Merck KgaA, Germany, Suprapur® 64271 
Trichloro-acetic acid: Lot 35H0783, SIGMA (St. Louis) 
Zinc stock standard (15295 umol/O： Perkin Elmer 
Zinc QC: Perkin Elmer Atomic Spectroscopy Standard, Lot 
No 5-94ZN 
Working standard: 
Std3 30.59 umoLT. (dilute stock standard x500 with 
2% nitric acid) 
Std2 20.39 umol/L (5 niL 2% nitric acid + 10 mL 
standard 3) 
Stdl 10.20 umoVL (10 mL 2% nitric acid + 5 mL 
standard 3) 
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Working Aqueous QC (Dilute aqueous 1530 ^ imol/L 
Q C X 100 with 2% nitric acid) 
II. Sample Preparation 
Mix 0.5 ml standard /QC/ patient sample with 2 ml 5% 
T C A in a 5 ml-size pp tube. Centrifuge at 3,000 rpm for 10 
minutes. Transfer the supernatant to another tube for 
analysis. 
III Instrument Setting 
wavelength 213.9 rnn 
slit width 0.7 nm 
read time 2.5 s 
read delay 0 s 
signal measurement time average 
flame type air/C2H2 
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oxidant flow 10.00 L/min 
fuel flow 3.00 L/min 
calibration equation zero intercept: linear 
3.2.3 DETERMINATION OF SERUM COPPER 
The determination of serum copper was completed on the 
A A S 300，Perkin Elmer Spectophotometer. 
1. Materials 
Reagent 
Nitric acid : Merck KgaA, Germany, Suprapur® 64271 
Trichloro-acetic acid: S I G M A , Lot 35H0783 
Copper stock standard (15734 umol/):Perkin Elmer 
Copper QC: Perkin Elmer Atomic Spectroscopy Standard, 
Lot No 5-9CU 
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Working standard: 
Std3 31.47 umol/L (dilute stock standard x500 with 
2% nitric acid) 
Std2 15.74 umoVL (5 m L 2% nitric acid + 10 m L 
standard3 ) 
Stdl 7.87 umolA. (15 m L 2% nitric acid + 5 m L 
standard3 ) 
Working Aqueous QC (Dilute aqueous 1573 umolA. 
Q C X 100 with 2 % nitric acid) 
n . Sample Preparation 
Mix 0.5 ml standard /QC/ patient sample with 2 ml 5% 
T C A in a 5 ml-size pp tube. Centrifuge at 3,000 rpm for 10 
minutes. Transfer the supernatant to another tube for 
analysis. 
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III. Instrument Setting 
wavelength 324.8 nm 
slit width 0.7 nm 
read time 2.5 s 
read delay 0 s 
signal measurement time average 
flame type air/C2H2 
oxidant flow 10.00 L/min 
fuel flow 3.00 L/min 
calibration equation zero intercept: linear 
replicates 2 
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3.2.4 DETERMEVATION OF SERUM SELENIUM 
The graphite ftimace atomic absorption 
spectrophotometer used in the measurement of selenium is 
Perkin Elmer SCVtMA 6000 Spectrophotometer. 
1. Materials 
Reagent: 
Nitric acid : Merck KgaA, Germany, Suprapur® 64271 
Triton X-100 SIGMA Lot No 27F-0013 
Modifier (0.5 m L 1% pd0^O3)2 + 0.3 m L 1% 
MgO^fO3)2 + 9.2 m L D.W.) 
Selenium stock standard (12665 umol/): Perkin Elmer 
Selenium QC: Perkin Ehner Atomic Spectroscopy Standard, 
Lot No 5-22SE 
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Working Aqueous QC 
reagent A: was prepared by diluting 1 m L stock(1266 
mol/1) to 200 m L with 2% nitric acid. The selenium 
concentration of A was 6.332 umoL^. 
(i) (High, 1.055 umol/L) 1 m L of(A) + 5 m L of2% nitric 
acid 
(ii) (Medium, 0.352 umolA.) 1 m L of (i) + 2 m L of 2% 
nitric acid 
(iii) (Low, 0.088umoL^) m L of (ii) + 3mL of2% nitric acid 
U. Sample Preparation: 
Mix 300 uL 0.25% Triton X-100 with 200 uL 
sample/QC in eppendorf tube. Centrifuge at 13.000 r.p.m. 
for 5 minutes. Transfer the &upematant to sample cup for 
analysis. 
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III. Instrument Setting 
The parameters were modified from the 
recommendation of the manufacturer. 
Wavelength 196 nm 
Read time 5 s 
Read delay 0 s 
Signal measurement peak area 
Sample volume 20 uL 
Modifier volume 10 uL 
Calibration equation zero intercept, linear 
Replicate . 2 
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Pipetting steps pipette diluent + modifier 
+ sample/std 
Pipetting speed 50% 
Fumace conditions ( C: compressed air, A: argon) 
"Sl^"""Temp~~~Ramp~~Hold~~Internal flow~~G^ Read~~ 
�C Time Time 
1 n o 1^  ^ ~ ~ ^ c 
2 130 10s 40s 250 C 
3 1200 15s 20s 250 A 
4 1900 Os 5s 0 A X 
5 2400 ls 5s 250 A 
IV. Contamination Preventing 
Due to the low serum selenium concentration, it is the 
analytes that would be most likely influenced by any 
contamination from the environment. Trace of selenium 
present in the sample tube could lead to a major effect on 
the observed results. Therefore, prevention of any selenium 
in the sample tube is examined in a prior study. Ten new 
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sample tubes that were used in routine blood collection were 
checked. 5 ml deionized double distilled water was injected 
through a new blood syringe into each of the sample tubes. 
The tubes were vortexed ovemight before the injected water 
sample was analyzed for selenium. 
All the ten samples used in evaluation of contamination 
showed a selenium concentration less than 0.008 |imol/L 
which are not different from the lower detection limit. 
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4 RESULTS 
4.1 RESULTS OF EVALUATION OF ANALYTICAL 
METHODS 
4.1.1 RESULTS OF METHODS EVALUATION OF SERUM 
ZINC ASSAY 
I. WITHlN-BATCH PRECISION (Table 4-1) 
Three samples of different levels were analyzed for 20 
replicates. 
Low Median High 
N 20 20 20 
Mean (^ imoLO.) 12.29 21.39 33.03 
. S D (^imoUL) 0.279 0.252 0.508 
C V 2.3% ， 1.2% 1.5% 
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IIBETWEEN-BATCH PRECISION (TABLE 4-2) 
Aqueou Q C Semm Q C 
N 14 14 
Mean(jimoVL) 16.13 22.59 
SD (|imoUL) 0.59 0.77 
C V 3.6% 3.4% 
III. ACCURACY (TABLE 4-3) 
10 TEQAS samples were analyzed, accuracy ranged 
from 100.6 — 109.5%. (TEQAS: external quality control 
sample from U K E Q A S trace elements scheme) 
IV. RECOVERY 
For samples with large volume of standard addition: 
(TABLE 4-4) 
Five samples with 6.12 [xmoUL zinc added, recovery 
ranged from 109.3-145.1%. 
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Five samples with 10.20 ^ imol/L zinc added, recovery 
ranged from 79.2-115.1%. 
For samples with small volume of standard addition: 
(TABLE 4-4) 
Five samples with 5.53 ^ imol/L zinc added, recovery 
ranged from 92.4-105.6%. 
Five samples with 10.67 ^ mol/L zinc added, recovery 
r a n g e d f r o m 9 1 . 0 - 9 4 . 8 % . 
V. LINEARITY AND DETECTION LIMITS 
(TABLE 4-6 & FIGURE 4-1) 
Zinc assay was performed on a serial dilution of a high 
concentration of standard to check the linearity of the 
assay. The linearity range was between 9.4 and 18.4 [i 
mol/L. 
The lowest detection limit was 1.6 ^ imolyT.. 
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4.1.2 RESULTS OF METHODS EVALUATION OF SERUM 
COPPER ASSAY 
L WITfflN-BATCH PRECISION (Table 4-7) 
Three samples of different levels were analyzed for 20 
replicates. 
Low Median High 
N 20 20 20 
Mean (^mol/L) 8.99 20.31 36.11 
SD (^moVL) 0.108 0.353 0.325 
C V 1.2% 1.7% 0.9% 
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II. BETWEEN-BATCH PRECISION (TABLE 4-8) 
Aqueou Q C Serum Q C 
N 14 14 
Mean (^imol/L) 16.13 19.51 ^ mol/L 
SD (^imol/L) 0.59 0.74 |imol/T. 
C V 3.6% 3.7% 
III. ACCURACY (TABLE 4-9) 
10 TEQAS samples were analyzed, accuracy ranged 
from 92.2 — 97.0%. 
IV. RECOVERY (TABLE 4-10) 
Five samples with 6.29 ^imol/L copper added, recovery 
ranged from 93.8-100.21%. 
Five samples with 10.49 ^imol/L copper added, 
recovery ranged from 101.6-104.3% 
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IV. LINEARITY AND DETECTION LEVIITS 
(TABLE 4-11 & FIGURE 4-2) 
Copper assay was performed on a serial dilution of a 
high concentration of standard to check the linearity of the 
assay. The linearity range was between 2.0 and 36.0 i^ 
mol/L. 
The lowest detection limit was 2.0 ^ imol/L. 
4.1.3 RESULTS OF METHODS EVALUATION OF SERUM 
SELENIUM ASSAY 
L PRECISION 
Precision study consisted of within-batch precision and 
between-batch precision. Within- batch precision (Table 4-
12) was performed by analyzing 20 replicates of low, 
medium and high level control sera. The controls used in this 
study were prepared by mixing patient samples. The low and 
high levels were obtained by dilution or by addition of 
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selenium. 
Between - batch precision (Table 4-13)was performed by 
analyzing one set of the low, medium and high concentration 
of Q C materials and a commercial Q C serum 
( S E R O N O R M ™ Trace Elements Serum, Batch no. 311089). 
The mean, SD and C V were then calculated and tabulated. 
II RECOVERY 
The basal serum sample was prepared and divided into 
five aliquots. Five different volumes of selenium standard 
(0.672 ^ imol/l) was added to each aliquot of basal sample. 
The selenium concentration of each sample were determined 
in triplicate. The average of each was used for the 
calculation. Recovery ranged from 94% to 103%. 
III LINEARITY AND DETECTION LIMITS 
(FIGURE 4-3) 
Selenium assay was performed on a serial dilution of a 
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high concentration of standard to check the linearity of the 
assay. The linearity range was between 0.021 and 15.0 ^  
molyT^ . The lowest detection limit was 0.021 ^ mol/L. 
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4.2 RESULTS OF PATIENTS STUDY 
4.2.1 CONTROL GROUP (Summary in Table 4-16) 
I. SERUM MAGNESIUM 
40 samples from this group were randomly selected for 
analysis. The mean was 0.9 mmol/L. The minimal level was 
0.57 mmol/L and the maximal level was 1.15 mmol/L. 
II. SERUM ZINC 
All 63 samples from this group were analyzed. The mean 
was 11.3 ^ imol/L. The minimal level was 4.0 ^imol/L and the 
maximal level was 17.16 ^ mol/L. 
III SERUM COPPER 
62 samples from this group were randomly selected for 
analysis. The mean was 18.0 ^imol/L. The minimal level was 
9.81 [imolfL and the maximal level was 28.2 |imol/L. 
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IV SERUM SELENIUM 
57 samples from this group were randomly selected for 
analysis. The mean was 0.87^mol/L. The minimal level was 
0.52 ^ imol/L and the maximal level was 1.65 ^ imol/L. 
4.2.2 PATIENTS WITH ACUTE MYOCARDIAL 
INFARCTION 
1. DEMOGRAPHIC DATA 
94 patients with A M I were investigated among which 66 
were male and 28 were female. The youngest patient was 33 
years and the oldest was 94 years old. The median age was 
67 years. 25% of patients were below 56 years old. (FIGURE 
4-4) 
IL GENERAL BIOCHEMICAL DATA 
1). PLASMA CREATINEVE ON ADMISSION 
The mean creatinine level was 111 ^mol/l in this 
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group of patient. It indicates that a high proportion of 
patients have poor renal ftinction. There are 50% of 
patients showing a creatinine level of great than 100 
i^rnol/l. (FIGURE 4-5) 
2). PLASMA ALBUMIN ON ADMISSION 
Most of the patient showed a low albumin on 
admission. More than 90% of patients had an albumin value 
less than 40 g/L while the median value was 33 g/L. 
(FIGURE 4-6) 
3). HAEMATOLOGICAL MARKERS OF NUTRITION 
STATUS 
� Haemoglobin 
Almost 25% of patients were anemic (Hb < 12 g/L). 
(FIGURE 4-7) 
� Mean corpuscular volume (MCV) 
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Few patients showed a low M C V suggestive of 
microcytic anemia (5%). Furthermore less than 5% of 
patients featured macrocytic red blood cells, which may 
indicate folate/B12 deficiency. (FIGURE 4-8) 
� White blood cell (normal range:4-10xl0^/L) 
Less than 5% of patients showed a low white cell 
count. 
4). TRACE ELEMENT STATUS IN AMI PATIENTS 
� .MAGNESIUM (normal range: 0.67- 1.01 ^ imol/L) 
10% of patients were found to have 
hypomagnesium(less than 0.67 ^mioLl^). The mean 
magnesium was 0.77 i^molyT., which was significantly 
lower than the control group( the mean magnesium of 
control group was 0.89 ^ molA., standard deviation was 
0.128 [imolfL). (FIGURE 4-9) 
� .Z I N C (normal range: 9.8 - 18.4 ^ imol/L) 
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A high proportion (more than 60%) of the A M I 
patient showed a zinc level lower than the lower 
reference limit of9.8 ^ imol/L). 
However, given the fact that plasma zinc decrease 
during early phase o f A M L W e classified patients with a 
zinc level lower than the lower 25 percentile value of 8 
|imol/L as having a marked reduction of semm zinc. 
Therefore 25% of patients were classified having an 
adverse level of semm zinc. (FIGURE 4-10) 
When compared to control group (mean of which is 
11.3 i^mol/L), A M I patients showed a significant low 
zinc level by t test (p<0.05). 
③.COPPER (normal range: 10.7- 25.2 ^ imoLO^) 
A high copper level was found in only a small 
proportion of A M I patients. Only 5% of patients has 
value greater than 24.5 p.mol/L. When the mean copper 
value was compared with the control group, there was no 
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significant difference. (FIGURE 4-11) 
� .S E L E N I U M 
The 5th and 95^ percentile value of selenium in A M I 
patients were 0.65 and 0.99 p.mol/L. However there was 
no difference between A M I patients and the control 
group. (FIGURE 4-12) 
III. PROGNOSTIC IMPLICATION OF SERUM 
LEVELS OF THE FOUR ELEMENTS 
A set of potentially important biochemical factors were 
analyzed for their effect on patients mortality. As the 
variables were continuous and not all are normally 
distributed, they were defined into dichomatous variables by 
using selected cut-off values (Table 4-17) 
The lower or upper reference levels were used for 
albumin, copper, magnesium, zinc. Plasma creatinine value 
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greater than 200 jLimoLT. which indicating a significantly 
impared glomerular filtration rate was taken as a high risk 
parameter. As the serum zinc and selenium have neither an 
appropriate reference interval during AMT nor a population 
reference intervals, the patients at the bottom 25^ percentile 
values were compared to the rest of the group. 
By cross table analysis with modified chi square statistics, 
those patients with a high serum creatinine and low zinc 
concentration showed higher mortality. (Table 4-18) 
The associations were furtherly analyzed with both 
univariate and multi-variate regression. (Table 4-19 & Table 
4-20) By univariate analysis, patients age was found to be 
associated with mortality in addition to high Cr and low zinc 
groups. After exclusion, of confounding effects by 
multivariate logistic regression, high age, high creatinine, low 
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low zinc were remained significantly associated with higher 
mortality and high copper/zinc ration which showed 
marginal significance in univariate analysis (Table 4-19) 
became significant. 
4.2.3 DIGOXIN GROUP 
I. MAGNESIUM 
There are about 20% of patients on treatment of digoxin 
showing hypomagnesemia. 10% of patients had serum 
magnesium levels below 0.628 ^ imol/L 
As a group, the mean magnesium level is lower than the 
control, which was 0.78 and 0.89 |imol/L respectively. 
II. ZINC 
There are 25% of patients had a serum zinc level below 8 
^mol/L. And almost 50% of them were below the lower limit 
of reference range (9.8 ^ mol/L). Although the mean zinc level 
was 10.6 p,mol/L which was lower than the control group, the 
83 
difference did not reach statistical significance. 
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5 DISCUSSION 
5.1 AMI PATIENTS AND TRACE ELEMENT STATUS 
L MAGNESIUM 
Hypomagnesemia was found in only approximately 10% 
of patients with MI at presentation to the hospital. And prior 
use of diuretic agents may contribute to hypomagnesemia. 
Hypomagnesemia was not a predictor of higher mortality. 
(Table 4-22) 
II. COPPER 
Although previous investigation have demonstrated 
elevated serum copper levels in patients with AMI, we found 
no difference between the A M I and the control group. 
III. ZINC 
W e identified low plasma zinc as an independent risk 
factor for mortality after AMI. Age and poor renal function 
were two well known factors affecting mortality which were 
also documented in the present study.(Table 4-21) 
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A plasma zinc level lower than 8 ^imol/L was associated 
with an increase in the chance of dying from AMI. 
IV. SELENIUM 
There was no difference between A M I patients and the 
control group. The results do not support the hypothesis that 
selenium level changes during acute myocardial infarction. 
And a low level of selenium during A M I was not associated 
with higher mortality. 
V. RISK FACTORS ASSOCIATED WITH 
MORTALITY AFTER AMI 
Age and impaired renal function were well known to 
influence the post-AMI survival. In addition, low serum 
zinc and high copper/zinc ratio were also significant for 
mortality in this study. 
There are a number of hypothesis which account for the 
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importance of these trace elements during A M L Zinc has 
been described to concentrate in the myocardial tissue to 
participate in the process ofrepair and thus a lower serum 
zinc may be an indication of the infarct size.[Speich.M et 
al, 1988]. 
On the other hand, as zinc is largely bound to albumin, a 
low zinc may be part ofresult of extravasation of albumin 
during acute phrase reaction. Therefore albumin was not an 
independent risk factor in multivariate analysis suggesting 
that this mechanism can not explain all the variation of 
serum zinc. As high copper to zinc ratio, which can be taken 
as a marker of acute phase reaction, is an independent factor 
for mortality, the role of acute phase reaction on the long 
term outcome of patient after A M I is likely present. 
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The low zinc level could be the result of long term 
nutritional deficiency. Patients with marginal zinc intake 
may become overtly hypozincemic during acute stress like 
AMI. As it is reported that zinc deficiency did lead to a 
large infarction size and poor survival in experimental 
animal. [Amaud J et al, 1991； 
Therefore multiple factors may exit to account for the 
link between low zinc and mortality. Further study is 
required to clarify the interplay of this factors and to derive 
a risk model for A M I patients. 
5.2 MAGNESIUM AND ZINC STATUS IN PATIENTS 
RECEIVING DIGOXIN TREATMENT 
Electrolyte imbalance, mainly of potassium and calcium, 
could precipitate digoxin toxicity even in patients treated 
with conventional dose of the drug. However, 
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hypomagnesemia is also an important risk factor fordigoxin 
toxicity, though it is rarely measured in patients treated with 
digoxin. 
In the group of patients studied, the overall magnesium 
level is lower than the control. It may suggest a generally 
poor food intake in these patients who were mostly suffered 
from heart failure and arrhythmia. Poor food intake in long 
term would potentially lead to hypomagnesemia and 
potentiate digoxin toxicity. It is alarming that 20% of the 
patients were hypomagnesemia, and almost half of them 
were severe (less than 0.6^imol/L). Therefore, determination 
of serum magnesium is indicated in long term management 
of patient on digoxin and appropriate supplement should be 
given when hypomagnesemia is confirmed. 
It is interesting to find that one fourth of patients had a 
low zinc level (below 8 ^ imoL^). It may indicate a long term 
ongoing acute phase reaction, but it may be unlikely for 
these to stable patients. A poor nutrition status may be a 
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possible explanation for the low serum zinc. Due to the 
nature of the study, samples were not adequate for further 
analysis of other nutrition markers, such as prealbumin for 
assess the protein nutritional status of these patients. A 
prevalence study for nutrition markers in these patients may 
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Table 1-1 R E C O M M E N D E D DIETARY ENTAKES OF M A G N E S I U M , 
ZD^C A N D SELENIUM ‘ 
A ^ Magnesium Zlm Selenium 
(years) (mg) (mg) (^ ig) 
Infants 0.0-0.5 40 5 ‘ fO 
0.5-2.0 60 5 15 
Children 1-3 80 10 20 
4-6 120 10 20 
7-10 170 10 30 
Males 11-14 270 15 40 
15-18 400 15 50 
19-22 350 15 70 
23-50 350 15 70 
51+ 350 15 70 
Females 11-14 280 12 45 
15-18 300 12 50 
19-22 280 12 55 
23-50 280 12 55 
51+ 280 12 55 
Pregnant 320 15 65 
Lactating 355 ^ 7_5  
Table 1-2 R E C O M M E N D E D DIETARY S T A K E S OF COPPER 
Age Copper 
(years) (mg)  
Infants 
0 - 0 . 5 0.4-0.6 
0.5-1 0.6-0.7 
Children & adolescents 
1 - 3 0.7-1.0 
4 - 6 1.0-1.5 
7 - 10 1.0-2.0 
11+ 1.5-2.5 
Adults 1.5-3.0 
TABLE 4-1 IMTRA-ASSAY PRECISION OF ZJNC ANALYSIS 
Low Median High 
(^mol/L) (^mol/L) (^mol/L)  
n J 0 21.41 32.36~~‘ 
12.15 21.04 32.74 
12.17 21.24 32.91 
12.22 21.29 32.70 
11.89 21.42 32.78 
11.96 21.23 33.31 
11.86 21.34 32.67 
11.94 21.51 32.99 
12.43 21.35 32.94 
12.74 21.60 33.00 
12.85 21.25 33.32 
12.18 21.36 32.78 
12.42 21.15 32.85 
12.41 21.60 32.58 
12.72 21.03 32.61 
12.15 21.36 34.30 
12.62 21.46 32.62 
12.32 21.22 33.22 
12.38 21.62 34.14 
12.30 22.22 3 3 ^  
TJ l o ^ ^ ~~ 
Mean 12.29 21.39 33.03 
SD 0.279 0.252 0.508 
C V 2.3% 1.2% 1.5% 
TABLE 4-3 A C C U R A C Y OF Z m C ANALYSIS 
TEQAS* Target mean Target result Accuracy 
(^imol/L) (^imol/L) 
l40 fl7 8 ^ • 107.9% 
441 11.00 12.05 109.50/0 
442 22.93 24.39 106.4% 
443 23.87 24.06 100.8% 
444 11.60 12.38 106.7% 
472 31.96 33.34 104.3% 
474 14.66 15.13 103.2% 
484 23.28 24.07 l03.4% 
485 8.44 8.49 100.6% 
486 32.82 33.76 i02.9% 
* TEQAS: External quality control sample from U K E Q A S trace 
elements scheme 
T A B L E 4-4 R E C O V E R Y OF ZDMC ANALYSIS (Large volume of 
standard added) 
Neat sample 6.12 ^ mol/l Zn added 10.20 ^ imol/L Zn added 
Zn conc Zn conc Recovery Zn conc Recovery 
(jumol/L) (^mol/TL) (^imolA.) 
~5J~l 13.55 — 131.4% 13.59 79.2%" 
7.27 16.15 145.1% 19.01 115.1% 
5.57 13.75 133.7% 17.18 H3.8% 
7.58 14.27 109.3% 18.29 105.0% 
7.968 15.22 118.5% 19.01 108.3% 
TABLE 4- 6 LINEARITY A N D DETECTION LIMIT OF Z W C 
ANALYSIS 
Expected concentration Results 
~0 — 0.055 * ‘ 
0.42 0.101 * 






















* R S D > 10% 
TABLE 4-7 WITHIN-BATCH PRECISION OF COPPER ANALYSIS 
Low Median High 
(^ iniol/L) (^ imol/l) (|umol/L)  
^ 19.40 3i:40 
8.82 19.80 35.70 
9.11 19.80 35.30 
9.03 20.00 35.80 
8.89 20.00 35.90 
9.12 20.20 36.50 
9.20 20.20 36.10 
9.00 20.20 36.30 
9.17 20.50 36.10 
8.89 20.40 36.40 
8.99 20.70 36.30 
8.85 20.30 36.30 
9.02 20.40 36.20 
9.02 20.50 36.10 
9.15 20.70 36.00 
9.00 20.40 36.30 
8.91 20.70 36.40 
8.94 20.60 36.40 
8.88 20.80 36.30 
^ 20.50 36.30 
Tf W ^ ^ 
Mean 8.99 20.31 36.11 
SD 0.108 0.353 0.325 
C V 1.2% 1.7% 0.9% 
TABLE 4-8 B E T W E E N - B A T C H PRECISION OF COPPER 
ANALYSIS 
Aqueous Q C Serum Q C  
(^ imolyl.) (^mol/L) 














Tf H H 
Mean 16.13 19.51 
SD 0.59 0.74 
C V 3.6% 3.7% . 
TABLE 4-9 A C C U R A C Y OF COPPER ANALYSIS 
TEQAS Target mean Target result Accuracy 
(^mol/L) (^mol/L) 
1S0 r ^ m 92.2% 
441 30.62 29.7 97.0% 
443 33.52 32.4 96.7% 
444 27.60 25.8 93.5% 
448 25.28 23.6 93.4% 
473 30.38 28.7 94.5% 
474 26.45 25.2 95.3% 
484 23.99 22.2 92.5% 
485 29.87 28.5 95.4% 
486 22.72 21.3 93.8% 
TABLE 4-10 R E C O V E R Y OF COPPER ANALYSIS (Large volume 
of standard added) 
Neat sample 6.29 ^ mol/l Cu added 10.49 ^ imol/L Cu added 
Cu conc Cu conc Recovery Cu conc ~~Recovery~ 
(|umol/L) (jLimol/L) (^unoLOL) 
T 4 9 rr? 98.7% K l "i02.1%  
7.14 13.4 99.5% 17.8 101.2% 
8.96 15.2 99 .2% 19.9 104.3% 
10.6 16.9 100.2% 21.4 103.0% 
12.3 18.2 93.8% 23.0 102.0% 
TABLE 4- 11 LENEARITY A N D DETECTION LIMIT OF COPPER 
ANALYSIS 
Expected concentration Results 
0 .00 — 0.05 * “ 
0.43 0.05 * 
0.54 0.21 
1.09 1.02 
1.63 1.63 * 



















* R S D > 10% 
TABLE 4-12 Within-batch PRECISION OF SELENIUM ASSAY: 
Mean~~N ^ 5 ~ ~ ^ " ~ M e a n + 2 S D ‘ 
(p-mol/L) 
High value: 1.145 22 0.07 1.3% 1.005〜1.285 
Medium value: 0.513 21 0.02 3.3% 0.473〜0.553 
Low value: 0.113 22 0.002 1.8% 0.109-0.117 
TABLE 4-13 B E T W E E N - B A T C H PRECISION OF SELENIUM 
ANALYSIS 
Mean~~~N ^ 5 ~ ~ C V Mean+2SD “ 
(p,mol/L) 
High value:""TJU~~fs~~0.051 4.2 % 0.130-1.300 ‘ 
Medium value: 0.500 18 0.020 4.0% 0.471-0.525 
Low value: 0.111 11 0.008 7.2% 0.097-0.120 
seronorm: 0.267 11 0.009 3.4% 0.254〜0.283 
TABLE 4-14 R E C O V E R Y OF SELENIUM A S S A Y 
Sample standard Expected detected recovery 
(0.270 ^ imol/l) ( 0.672 ^ imol/l) value value 
(1) 0.3 ml 0.1 ml 0.371 0.382 103% 
(2) 0.3 ml 0.2 ml 0.431 0.422 98% 
(3) 0.3 ml 0.3 ml 0.471 0.445 94% 
(4) 0.3 ml 0.4 ml 0.500 0.479 96% 
(5) 0.3 ml 0.5 ml 0.521 0.537 103% 






























































































































































































































































TABLE 4-17 CLASSIFICATION OF A D V E R S E BIOCHEMICAL 
FACTORS 
Adverse factors Def ine Remark 
Low albumin Albumin < 30 g/L Lower reference limit 
High copper Copper > 25g/L Upper reference limit 
Low magnesium Magnesium < 0.67 [i Lower reference limit 
mol/L 
Low selenium Selenium < 0.72 i^ Lower 25^ ^ percentile 
niol/l ofAMI 
Low zinc Zinc < 8 ^ mol/L Lower reference limit 
Hcopper-zinc Cu-Zn > 2.2 Upper 25^ percentile 
ofAMI 
Hcreatinine Creatinine > 200 ^ Poor renal function . 
molA^ 
TABLE 4-18 RESULT OF CHI-SQUARE ANALYSIS OF THE 
RELATIONSHIP B E T W E E N INDIVIDUAL A D V E R S E FACTORS 
A N D SURVIVAL AFTER A M I 
Adverse factors Chi-square value Fisher's exact test 
High Creatinine 11.2 * 
High copper 2.9 
Low magnesium 0.11 
Low zinc 3.9 * 
Low selenium 0.959 
High Cu/Zn 1.99 
* P<0.05 
TABLE 4-20 Multivariate Relation Between Various Demographic, 
clinical, and Biochemical Variables and Mortality After MI ’ 
Factors . |P: ., Exp(B) 
Age 0.0008 0.846 
High creatinine 0.015 0.038 
High Cu/Zn 0.048 12.45 
Low zinc 0.0072 34.99 
Table 4-21 SURVIVAL 一 L O W ZINC CROSSTABULATION 
Low zinc Normal zinc Total 
" D ^ ^ f3 n ~ ~ 
Survival 14 56 70 
Total 23 69 92~~" 
Table 4-22 S U R V I V A L - L O W M A G N E S I U M CROSS 
TABULATION 
Low M g Normal M g Total 
Dead Tl 3 ^ ^ 
Survival 63 7 70 
Total 84 10 94 
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